COOPERATIVE STUDY OF CANCER CHEMOTHERAPY

患有癌症的患者将接受III期方案的治疗， 西南肿瘤学小组采用跨学科方法， 手术、放疗、化疗（包括可变时间表， 联合用药，包括研究药物和已经 已被证实和接受的药物，无论是单独使用还是与 放疗;这些形式的治疗将代表目前最 通过分组研究确定的有效药物组合），以及 免疫疗法 对上述治疗无反应的患者将 使用新的实验药剂进行管理，这些药剂已经过仔细评估 剂量和毒性，并显示抗肿瘤的提示性证据 在特定恶性肿瘤中的作用。 这些将代表第二阶段 西南肿瘤组的研究方案。 使用上述评价的患者材料的辅助研究 协议将与其他部门的研究活动协调 在病理学、免疫学、生物化学、药理学和 通过独立的赠款支持解剖。

Patients who have cancer will be treated with Phase III protocols of the Southwest Oncology Group in an interdisciplinary approach utilizing surgery, radiotherapy, chemotherapy (which includes variable schedules and combinations of drugs, including both investigational agents and already proven and accepted drugs, either alone or in combination with radiotherapy; these forms of therapy would represent the current most effective drug combinations identified by group studies), and immunotherapy. Patients who are unresponsive to the above therapy will be managed with new experimental agents, which have been carefully evaluated for dosage and toxicity, and which show suggestive evidence of anti-tumor effect in specific malignancies. These will represent the Phase II protocol studies of the Southwest Oncology Group. Ancillary studies utilizing patient material being evaluated in the above protocols will be coordinated with research activities of other departments in the areas of pathology, immunology, biochemistry, pharmacology, and anatomy through independent grant support.